AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02389452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synvisc-One
Description: intraarticular injection
Study NCT01134172 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey web-based or telephone interview
Description: Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
Study NCT01134172 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey web-based or telephone interview
Description: Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
Study NCT03013153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low ligation with apical lymph node dissection
Description: Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
Study NCT03013153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High ligation
Description: High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
Study NCT01367925 — intervention group
Intervention type: DEVICE
Intervention: Stryker Triathlon® CS Tibial Insert
Study NCT01367925 — intervention group
Intervention type: DEVICE
Intervention: Stryker Triathlon® PS Tibial Insert
Study NCT00091819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB052793
Description: Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone administered orally at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib administered intravenously at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide administered orally at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB052793
Description: INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide administered orally at the protocol-specified dose and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
Study NCT02265510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB039110
Description: INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
Study NCT01515124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
Study NCT01515124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention
Description: The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
Study NCT01668797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole tablets 1 to 4 mg /day
Study NCT01668797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator for 52 weeks
Study NCT01004614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 3rd OD 5 mg tablet single oral dose administered with water
Study NCT01004614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 2nd OD 5 mg tablet single oral dose administered with water
Study NCT01178697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevasizumab
Description: Intravitreal, 1.25 mg, 3 times, one month apart.
Study NCT01178697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal, 2 mg, 2 times, two months apart.
Study NCT02940600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion
Description: Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
Study NCT02940600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static cold storage
Description: Patients undergoing liver transplant using statically cold preserved grafts
Study NCT01883232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onset Mixing Pen by Onpharma
Description: Sodium Bicarbonate 8.4%
Study NCT01883232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: 2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
Study NCT03167359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Simultaneous Integrated Boost Radiotherapy
Description: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
Study NCT01004614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 3rd OD 5 mg tablet single oral dose administered without water
Study NCT01004614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 2nd OD 5 mg tablet single oral dose administered without water
Study NCT00942643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP machine
Description: a machine delivers positive airway pressure into the upper airway via a nasal mask
Study NCT02923869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
Study NCT02923869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
Study NCT04468711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D plus topical 1% hydrocortisone cream twice daily
Study NCT04468711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus topical 1% hydrocortisone cream twice daily
Study NCT03794596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Colourless odourless aqueous solution for infusion at dose of 10mg/kg
Study NCT04476368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekly yoga classes
Description: Weekly 90 min pregnancy-adapted yoga classes lead by certified yoga instructors.
Study NCT04476368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walk
Description: 20-30 min easy walking
Study NCT01291823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: gefitinib 250mg/day
Study NCT03794596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg tablets
Study NCT03794596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole (Proton Pump Inhibitor)
Description: 300mg capsule
Study NCT03044418 — intervention group
Intervention type: OTHER
Intervention: Application of ET laser tube in propofol anesthesia
Description: The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
Study NCT01727921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge ProCore needle biopsy
Description: 22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
Study NCT01727921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge ProCore needle biopsy
Description: 25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
Study NCT05151913 — intervention group
Intervention type: OTHER
Intervention: Exploratory
Description: Fecal microbiome
Study NCT02240329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological Testing and Measures of TBI severity
Description: A brief cognitive assessment will be given to each participant when he or she presents for this project.
Study NCT02240329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Respiratory measures
Description: We will collect measures of cough airflow and breathing strength.
Study NCT02240329 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin cough sensitivity testing
Description: Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
Study NCT00922311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Titrate from 150 mg daily to 300 mg daily
Study NCT02530775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: instrumented spinal fusion with laminectomy
Description: Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach.
Study NCT02530775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-instrumented spinal fusion with laminectomy
Description: Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach.
Study NCT02671968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 1
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 2
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 3
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 4
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01291823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy 54-60Gy over 30 fraction
Study NCT01813877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDOPA PET/CT
Description: Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
Study NCT04523389 — intervention group
Intervention type: BIOLOGICAL
Intervention: analysis (protein, lipid, RNA ...) of circulating exosomes, size and number
Description: use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
Study NCT02832037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03316105 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Elira Investigational TENS device
Description: TENS unit placed on skin will deliver electric stimulation to abdominal area.
Study NCT03316105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elira Investigational TENS device
Description: TENS unit placed on skin will deliver electric stimulation to abdominal area.
Study NCT04523389 — intervention group
Intervention type: OTHER
Intervention: Gathering additional information about the patient's cancer
Description: Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
Study NCT04523389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Diagnostic test
Study NCT01010347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Splint
Description: A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
Study NCT01010347 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cast
Description: A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
Study NCT01543854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: Intravenous infusion of RLX030 over 20 hrs
Study NCT01543854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo over 20 hours
Study NCT01038765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: 8-weeks group based intervention of mindfulness and cognitive behavioural techniques
Study NCT06004960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CCX168
Description: Administered orally.
Study NCT05853263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol IV to substitute morphine IV.
Study NCT05853263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: standard care
Study NCT03668210 — intervention group
Intervention type: PROCEDURE
Intervention: Isokinetic evaluation
Description: Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
Study NCT02966327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral leg compression stockings
Description: Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
Study NCT02966327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized exercise
Description: Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
Study NCT01513655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTNIV
Description: LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
Study NCT04383132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: abdominal binder is a kind of elastic abdominal compression device
Study NCT04383132 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Abdominal Binder
Description: abdominal binder is a kind of elastic abdominal compression device
Study NCT02357459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single 5 mL IA injection
Study NCT02357459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 5 mL IA injection
Study NCT02357459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40
Description: Single 1 mL IA injection
Study NCT02699164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRX 9000, Axiom Worldwide, Tampa, Florida
Description: non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
Study NCT02966327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymphedema risk reduction
Description: Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
Study NCT02966327 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lymphedema risk reduction
Description: Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
Study NCT01681901 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound imaging
Description: Undergo ultrasound
Study NCT02710318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic immunization alert
Description: Immunization alert in the electronic health record
Study NCT01142232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Melphalan during autologous stem cell transplantation
Description: Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
Study NCT01142232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Description: Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.